2025-05-30 - Analysis Report
Okay, here's an analysis of Merck & Co Inc (MRK) based on the data you provided. The report is structured to include key figures, followed by a concise analysis of each section and a final overall assessment.

**Report on Merck & Co Inc (MRK)**

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** MRK
*   **Company Description:** Merck & Co Inc is a global pharmaceutical company that develops and manufactures a wide range of healthcare products.
*   **MRK Cumulative Return:** -1.96%
*   **VOO Cumulative Return:** 82.09%
*   **Relative Divergence:**
    *   Max: 23.9
    *   Min: -85.2
    *   Current: -84.1
    *   Relative Divergence (Position within range): 1.0

**Analysis:**

MRK has significantly underperformed the S&P 500 (VOO) over the period covered by the cumulative returns. The relative divergence of 1.0 indicates that MRK's underperformance is near its historical worst compared to the S&P 500 within the observed range.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha  | Beta  | Cap(B) |
|------------|--------|--------|--------|-------|--------|
| 2015-2017  | 5.0%   | 58.4%  | -24.0% | 0.0   | 108.3  |
| 2016-2018  | 42.0%  | 66.6%  | 24.0%  | 0.1   | 151.6  |
| 2017-2019  | 40.0%  | 66.6%  | 11.0%  | 0.2   | 185.4  |
| 2018-2020  | 19.0%  | 66.6%  | -6.0%  | 0.4   | 172.0  |
| 2019-2021  | -1.0%  | 65.6%  | -55.0% | 0.5   | 175.1  |
| 2020-2022  | 13.0%  | 69.3%  | 7.0%   | 0.5   | 261.6  |
| 2021-2023  | 35.0%  | 69.3%  | 19.0%  | 0.3   | 264.2  |
| 2022-2024  | -6.0%  | 69.3%  | -23.0% | 0.3   | 247.7  |
| 2023-2025  | -55.0% | 70.3%  | -85.0% | 0.3   | 191.8  |

**Analysis:**

*   **CAGR:** Fluctuating performance, with recent years showing significant negative growth (-55.0% in 2023-2025).
*   **MDD:** High Maximum Drawdown across all periods, indicating significant volatility.
*   **Alpha:**  Inconsistent alpha generation. Recent years show strong negative alpha, suggesting underperformance relative to its risk-adjusted benchmark.
*   **Beta:** Low Beta values generally, indicating lower sensitivity to market movements compared to the S&P 500.
*   **Cap(B):**  Market capitalization has seen considerable fluctuations but remains substantial.

**2. Recent Stock Price Movement**

*   **Current Price:** 76.40
*   **Last Market Data:**
    *   Price: 76.4
    *   Previous Close: 76.17
    *   Change: 0.3
*   **5-Day Moving Average:** 77.116
*   **20-Day Moving Average:** 78.0105
*   **60-Day Moving Average:** 83.634

**Analysis:**

The stock price is currently below its 5, 20, and 60-day moving averages, suggesting a short-term downtrend. The slightly positive change from the previous close indicates a minor rebound, but the overall trend remains negative based on the moving averages.

**3. Technical Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.366 (Low Risk)
*   **RSI:** 47.08 (Neutral)
*   **PPO:** 0.2129
*   **Hybrid Signal:** "cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.37)"
*   **Recent (20-day) Relative Divergence Change:** -2.3 (Negative - Short-term decline)
*   **Expected Return (%):** -1109.9%

**Analysis:**

*   The MRI indicates a low-risk environment.
*   The RSI of 47.08 is neutral, suggesting neither overbought nor oversold conditions.
*   The Hybrid Signal recommends a cautious buy, aligning with the MRI indicating low risk.
*   The negative change in relative divergence and the extremely negative expected return are concerning, signaling potential long-term underperformance compared to the S&P 500.
*   The price change from the previous close is a small positive movement, and given that the price change is quite small, there is no significant "jump" to report on.

**4. Recent News & Significant Events**

*   **2025-05-30:** Major business developments, regulatory changes, or market events.
*   **2025-05-28:** Analysts discussing MRK's performance in the context of industry trends and global economic factors.
*   **2025-05-26:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **2025-05-29:** Market experts highlighting both risks and opportunities, advising investors to monitor news and company announcements.

**Analysis:**

Recent news indicates volatility and significant developments impacting MRK. Analysts' discussions and expert advice to monitor news suggest potential uncertainty and the need for careful evaluation of the company's prospects.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue    |
|------------|------|------------|
| 2025-05-02 | 2.01 | 15.53 B$   |
| 2024-11-06 | 1.25 | 16.66 B$   |
| 2024-08-05 | 2.15 | 16.11 B$   |
| 2024-05-03 | 1.88 | 15.78 B$   |
| 2025-05-02 | 1.88 | 15.78 B$   |

**Analysis:**

EPS and revenue have fluctuated over the recent quarters. The latest EPS is positive, but the revenue has shown mixed performance.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-03-31 | $15.53B    | 77.98%        |
| 2024-12-31 | $15.62B    | 75.50%        |
| 2024-09-30 | $16.66B    | 75.51%        |
| 2024-06-30 | $16.11B    | 76.76%        |
| 2024-03-31 | $15.78B    | 77.56%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE    |
|------------|------------|--------|
| 2025-03-31 | $48.34B    | 10.51% |
| 2024-12-31 | $46.31B    | 8.08%  |
| 2024-09-30 | $44.50B    | 7.09%  |
| 2024-06-30 | $43.58B    | 12.52% |
| 2024-03-31 | $40.36B    | 11.80% |

**Analysis:**

*   **Revenue:** Shows slight fluctuations.
*   **Profit Margin:** Remains relatively high and stable.
*   **Equity:** Exhibits a growing trend.
*   **ROE:** Fluctuates, indicating varying levels of profitability relative to equity.

**7. Overall Assessment**

Based on the provided data, Merck & Co Inc (MRK) presents a mixed investment picture:

*   **Underperformance:** MRK has significantly underperformed the S&P 500.
*   **Volatility:** High MDD indicates significant price fluctuations.
*   **Recent Downtrend:** The stock price is below its moving averages, indicating a short-term downtrend.
*   **Low Risk, Cautious Buy:**  MRI suggests low market risk, and the Hybrid Signal advises a cautious buy, though the negative expected return is concerning.
*   **Mixed Financials:** Revenue and earnings have been inconsistent, but profit margins remain strong, and equity is growing.
*   **News & Events:** Recent news indicates volatility and significant company-specific developments, suggesting uncertainty.
* **The most recent CAGR of -55.0% (2023-2025) is alarming and requires further investigation.**

**Recommendation:**

Given the significant underperformance, recent downtrend, extremely negative expected return, and uncertain news environment, **caution is advised** before investing in MRK. Further investigation into the reasons for the underperformance, the nature of the recent company developments, and a more detailed analysis of financial statements are warranted. It might be prudent to avoid MRK until there are clearer signs of a turnaround.
